Taiho, Cullinan’s lung cancer drug passes Phase 3 test, lining up Rybrevant contestnews2026-08-13T11:11:47+00:00August 13th, 2026|Endpoints News|
Vaccine makers throw cold water on separating MMR vaccinenews2026-08-12T18:17:06+00:00August 12th, 2026|Endpoints News|
Definium’s LSD drug clears bar in first of two Phase 3 anxiety disorder trialsnews2026-08-12T11:00:54+00:00August 12th, 2026|Endpoints News|
Epicrispr secures $90M after early data on epigenetic FSHD treatmentnews2026-08-11T12:54:59+00:00August 11th, 2026|Endpoints News|
Sionna’s surprise cystic fibrosis trial failure sinks hopes of challenging Vertexnews2026-08-10T15:39:45+00:00August 10th, 2026|Endpoints News|
AbCellera details ‘striking’ Phase 2 data for vasomotor symptoms treatmentnews2026-08-10T15:33:49+00:00August 10th, 2026|Endpoints News|
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancernews2026-08-10T11:31:25+00:00August 10th, 2026|Endpoints News|
China biotech will slow as it nears R&D frontier, Pfizer’s Baum predictsnews2026-08-07T15:00:01+00:00August 7th, 2026|Endpoints News|
FDA details pilot plan to expedite new drugs, eyeing up to 10 programsnews2026-08-06T19:16:03+00:00August 6th, 2026|Endpoints News|
Intellia identifies genetic risk factor for liver complications in CRISPR trialnews2026-08-06T15:33:40+00:00August 6th, 2026|Endpoints News|
